View Future GrowthBriaCell Therapeutics 과거 순이익 실적과거 기준 점검 0/6BriaCell Therapeutics의 수입은 연평균 -4.6%의 비율로 감소해 온 반면, Biotechs 산업의 수입은 연간 30% 증가했습니다.핵심 정보-4.64%순이익 성장률38.57%주당순이익(EPS) 성장률Biotechs 산업 성장률17.04%매출 성장률n/a자기자본이익률-99.17%순이익률n/a최근 순이익 업데이트31 Jan 2026최근 과거 실적 업데이트업데이트 없음모든 업데이트 보기Recent updatesBriacell Therapeutics Corp Announces Clinical Data Presentations for Bria-IMT and Bria-Abc in Metastatic Breast CancerApr 29Briacell Therapeutics Corp Presents Robust Anti-Cancer Activity of Bria-Ots+ in Preclinical Cancer ModelsApr 23BriaCell Therapeutics Corp. Presents Positive Phase 3 Quality Of Life And Phase 2 Biomarker Data at 2026 AACR MeetingApr 22BriaCell Therapeutics Corp. Receives Positive Recommendation from Data Safety Monitoring Board for Phase 3 Study in Metastatic Breast CancerFeb 17BriaCell Therapeutics Corp. Announces Patients' Images Show Regression and Resolution of Metastasized Tumors and Immune ActivationJan 28BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer PatientsJan 27BriaCell Therapeutics Corp. has completed a Composite Units Offering in the amount of $29.998959 million.Jan 16New major risk - Market cap size Jan 15Briacell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS PatientJan 13BriaCell Therapeutics Corp., Annual General Meeting, Mar 05, 2026Jan 12New major risk - Share price stability Dec 24BriaCell Therapeutics Corp. Announces Its Phase 3 Bria-Imt Clinical Trial in Metastatic Breast Cancer Has Been Featured in the Nature Medicine YearDec 19BriaCell Therapeutics Corp. Announces Phase 3 Patient Enrollment on Track for 1H2026 Topline Data ReadoutDec 09BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+ At SITC 2025Nov 07New major risk - Revenue and earnings growth Nov 06Briacell Receives Positive Recommendation from Data Safety Monitoring Board for Phase 3 Study in Metastatic Breast CancerOct 22+ 1 more updateBriacell to Present Positive Clinical Biomarker Data of Phase 3 Study At Esmo 2025Oct 14BriaCell Therapeutics Corp. Announces that it has been Awarded $2 Million NCI Grant to Advance Bria-PROS+ in Prostate CancerAug 25Briacell Adds Ucla Health as Key Site in Pivotal Phase 3 Breast Cancer StudyJul 31BriaCell Therapeutics Corp. has completed a Composite Units Offering in the amount of $14.998775 million.Jul 17New major risk - Market cap size Jul 16BriaCell Therapeutics Corp. Adds Mayo Clinic to Phase 3 Study in Metastatic Breast CancerJul 15Briacell's Bria-Imt™? Demonstrates Survival Advantage over Trodelvy®? and Control Group in Metastatic Breast CancerJul 11New major risk - Share price stability Jul 10Briacell Reports Complete and Sustained Resolution of Brain Metastasis and Sustained Regression of Orbital Metastasis in "Eye-Bulging" Breast Cancer PatientJul 10Briacell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-Ots™? Metastatic Breast Cancer StudyJul 09Briacell Therapeutics Corp. Reports Updated Survival Data from Its Ongoing Phase 2 Clinical Study of Bria-Imt in Patients with Metastatic Breast CancerJul 08Briacell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital At Yale New HavenJul 02BriaCell Announces Positive Recommendation from Data Safety Monitoring Board for Pivotal Phase 3 Study in Metastatic Breast CancerJun 24New major risk - Financial position Jun 17BriaCell Therapeutics Corp. Reports Robust Overall Survival and Clinical Benefit Data at ASCO2025Jun 03BriaCell Bria-OTS™ Phase 1/2 Study Clears Safety Evaluation; Doses First Patient in Combination with Checkpoint InhibitorMay 27BriaCell Therapeutics Corp. Abstracts Showcase Positive Survival and Clinical Benefit Data At ASCO 2025May 23BriaCell Therapeutics Corp. Reports " Late-Breaker" Phase 3 Data at AACR 2025: Positive Tolerability Profile and Potential Response Biomarkers IdentifiedApr 30BriaCell Therapeutics Corp. Presents Benchmark Beating Survival and Clinical Benefit at AACR 2025Apr 28BriaCell Therapeutics Corp. has completed a Composite Units Offering in the amount of CAD 13.8 million.Apr 26Briacell Confirms 100% Resolution of Lung Metastasis with Bria-OTSApr 24Briacell Therapeutics Corp. Enrollment Pace Accelerating in Phase 3 Clinical Study in Advanced Metastatic Breast Cancer (Bria-ABC)Apr 22Briacell Therapeutics Corp. Announces New Positive Survival Data in Its Phase 2 Study of Bria-Imt Plus Check Point InhibitorsApr 16BriaCell Therapeutics Corp. Announces Second Data Safety Monitoring Board Issues Positive Recommendation to Continue BriaCell's Phase 3 Study in Metastatic Breast CancerMar 20BriaCell Therapeutics Corp. has completed a Follow-on Equity Offering in the amount of CAD 3.05 million.Feb 06BriaCell Therapeutics Corp. has filed a Follow-on Equity Offering.Feb 05Briacell Announces Resolution of Lung Metastasis in First Patient Treated with Bria-OTSFeb 04New major risk - Revenue and earnings growth Feb 03Insufficient new directors Feb 02New major risk - Financial position Dec 18BriaCell Therapeutics Corp. has completed a Composite Units Offering in the amount of $5.55 million.Dec 13BriaCell Therapeutics Corp. Presents Unprecedented Overall Survival Data in Metastatic Breast Cancer in Spotlight Poster at 2024 SBCS®Dec 12BriaCell Receives Green-Light from Data Safety Monitoring Board for Its Phase 3 Study in Metastatic Breast CancerDec 02Insufficient new directors Dec 01BriaCell Therapeutics Corp. Accepts the Resignation of Marc Lustig from the Board of DirectorsNov 26Briacell Announces First Patient Dosed with Bria-OTS™ in Metastatic Breast Cancer StudyNov 21BriaCell Therapeutics Corp., Annual General Meeting, Jan 23, 2025Nov 18BriaCell Therapeutics Corp. Showcases Robust Anti-Cancer Activity of Personalized Off-the-Shelf Immunotherapy Pipeline at the 2024 SITC ConferenceNov 08Briacell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival DataOct 22BriaCell Therapeutics Corp. Provides Phase 3 Clinical Engagement Update in Metastatic Breast Cancer Pivotal StudyOct 15BriaCell Therapeutics Corp. has filed a Follow-on Equity Offering.Oct 03+ 1 more updateBriaCell Therapeutics Corp. Reports 100% Resolution of Brain Metastasis in Breast Cancer Patient with "Eye-Bulging" TumorOct 02Insufficient new directors Oct 01Price target decreased by 14% to US$15.00 Sep 19BriaCell Announces FDA-Authorized Expanded Access Policy for Metastatic Breast Cancer PatientsSep 18New major risk - Financial data availability Sep 16New major risk - Shareholder dilution Sep 15BriaCell Therapeutics Corp. has completed a Follow-on Equity Offering in the amount of $8.50425 million.Sep 13BriaCell Therapeutics Corp. has filed a Follow-on Equity Offering in the amount of $8.50425 million.Sep 12BriaCell Therapeutics Corp. Announces Positive Overall Survival Data of its Phase 2 Clinical Study of Bria-IMT in Combination with an Immune Check Point InhibitorSep 11BriaCell Announces Positive Pre-IND Meeting with FDA for Bria-PROS+ for Prostate CancerSep 10BriaCell Therapeutics Receives Deficiency Letter from Nasdaq Due to Non-Compliance with the Minimum Bid Price RequirementAug 26BriaCell Therapeutics Corp. Quadruples Progression Free Survival (Pfs) in Patient with "Eye-Bulging" Metastatic Breast CancerJul 19BriaCell Therapeutics Receives Letter from Nasdaq Due to Non-Compliance with the Minimum Market Value of Listed Securities Requirement Pursuant to Nasdaq Listing Rule 5550(b)(2)Jul 06Briacell Therapeutics Corp. Presents Clinical Efficacy Data At ASCO 2024Jun 05BriaCell Therapeutics Corp. Initiates Patient Enrollment in First-In-Human Study of Bria-Ots in Advanced Metastatic Breast CancerMay 31New minor risk - Shareholder dilution May 23Independent Director recently bought US$2.0m worth of stock May 22BriaCell Therapeutics Corp. has completed a Follow-on Equity Offering in the amount of $4.80586 million.May 18BriaCell Therapeutics Corp. has filed a Follow-on Equity Offering in the amount of $5 million.May 16BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+™ and Bria-PROS+™ Clinical Candidates for Breast and Prostate CancerApr 10New major risk - Negative shareholders equity Mar 20BriaCell Therapeutics Corp. Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder CaseFeb 08Briacell Therapeutics Corp. Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates Gmp ManufacturingFeb 07BriaCell Therapeutics Corp. Reports 71% Central Nervous System Response Rate in Advanced Breast Cancer PatientsDec 29BriaCell Therapeutics Corp. Reports Unprecedented Preliminary Survival and Clinical Benefit in Antibody-Drug Conjugate Refractory Patient SubsetDec 20BriaCell Therapeutics Corp. Highlights Outstanding Topline Survival and Clinical Benefit Data in Advanced Metastatic Breast Cancer at the 2023 SABCSDec 06BriaCell Therapeutics Corp., Annual General Meeting, Jan 30, 2024Dec 02BriaCell Therapeutics Corp. Announces Anew Remarkable Responder in Phase 2 Study of the Bria-IMT Combination RegimenDec 01BriaCell Reports Unprecedented Anti-Tumor Activity of its Next Generation Personalized Breast and Prostate Cancer Immunotherapies in Tumor Models at the 2023 SITC Annual Meeting; FDA Greenlights Bria-OTS™ INDNov 04New minor risk - Share price stability Nov 04New major risk - Financial position Oct 27BriaCell Therapeutics Corp. Forms Medical Advisory Board of Distinguished Breast Cancer Specialists to Advance its Lead Oncology CandidateOct 26BriaCell Therapeutics Corp. Initiates Pivotal Phase 3 Study of Bria-Imt™ in Advanced Metastatic Breast CancerOct 05BriaCell Therapeutics Corp. Reports Benchmark-Beating Patient Survival and Clinical Benefit in Advanced Metastatic Breast CancerSep 09BriaCell Therapeutics Corp. completed the Spin-Off of 33.33% stake in Pre-Clinical Assets of BriaCell Therapeutics Corp.Sep 01+ 1 more updateBriacell Receives National Cancer Institute Grant to Advance Its Bria-Ots™ Immunotherapy for CancerAug 17FDA Approves BriaCell’s Pivotal Registrational Study Design in Advanced Metastatic Breast CancerJun 28BriaCell Therapeutics Corp. Announces Positive End of Phase II Meeting with the FDA for Bria-IMT™ Combination in Advanced Metastatic Breast CancerJan 19Independent Chairman of the Board recently bought US$118k worth of stock Dec 23매출 및 비용 세부 내역BriaCell Therapeutics가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이NasdaqCM:BCTX 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비31 Jan 260-3072431 Oct 250-2972431 Jul 250-2662130 Apr 250-1961831 Jan 250-1262131 Oct 240-1762431 Jul 240-572730 Apr 240-682731 Jan 240-1382331 Oct 230-1381831 Jul 230-2091530 Apr 230-1881331 Jan 230-2381131 Oct 220081031 Jul 220-278830 Apr 220-426531 Jan 220-308431 Oct 210-416331 Jul 210-145230 Apr 21024231 Jan 210-21131 Oct 200-31231 Jul 200-42230 Apr 200-41331 Jan 200-52331 Oct 190-51401 Aug 190-51430 Apr 190-51431 Jan 190-52331 Oct 180-42331 Jul 180-41230 Apr 180-31231 Jan 180-31231 Oct 170-31231 Jul 170-31230 Apr 170-20131 Jan 170-11131 Oct 160-21131 Jul 160-21130 Apr 160-22031 Jan 160-21031 Oct 150-310양질의 수익: BCTX 은(는) 현재 수익성이 없습니다.이익 마진 증가: BCTX는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: BCTX은 수익성이 없으며 지난 5년 동안 손실이 연평균 4.6% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 BCTX의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: BCTX은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(40.2%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: BCTX는 현재 수익성이 없으므로 자본 수익률이 음수(-99.17%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/04 19:41종가2026/05/04 00:00수익2026/01/31연간 수익2025/07/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스BriaCell Therapeutics Corp.는 2명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Emily BodnarH.C. Wainwright & Co.Ashok KumarThinkEquity LLC
Briacell Therapeutics Corp Announces Clinical Data Presentations for Bria-IMT and Bria-Abc in Metastatic Breast CancerApr 29
Briacell Therapeutics Corp Presents Robust Anti-Cancer Activity of Bria-Ots+ in Preclinical Cancer ModelsApr 23
BriaCell Therapeutics Corp. Presents Positive Phase 3 Quality Of Life And Phase 2 Biomarker Data at 2026 AACR MeetingApr 22
BriaCell Therapeutics Corp. Receives Positive Recommendation from Data Safety Monitoring Board for Phase 3 Study in Metastatic Breast CancerFeb 17
BriaCell Therapeutics Corp. Announces Patients' Images Show Regression and Resolution of Metastasized Tumors and Immune ActivationJan 28
BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer PatientsJan 27
BriaCell Therapeutics Corp. has completed a Composite Units Offering in the amount of $29.998959 million.Jan 16
BriaCell Therapeutics Corp. Announces Its Phase 3 Bria-Imt Clinical Trial in Metastatic Breast Cancer Has Been Featured in the Nature Medicine YearDec 19
BriaCell Therapeutics Corp. Announces Phase 3 Patient Enrollment on Track for 1H2026 Topline Data ReadoutDec 09
Briacell Receives Positive Recommendation from Data Safety Monitoring Board for Phase 3 Study in Metastatic Breast CancerOct 22+ 1 more update
BriaCell Therapeutics Corp. Announces that it has been Awarded $2 Million NCI Grant to Advance Bria-PROS+ in Prostate CancerAug 25
BriaCell Therapeutics Corp. has completed a Composite Units Offering in the amount of $14.998775 million.Jul 17
Briacell's Bria-Imt™? Demonstrates Survival Advantage over Trodelvy®? and Control Group in Metastatic Breast CancerJul 11
Briacell Reports Complete and Sustained Resolution of Brain Metastasis and Sustained Regression of Orbital Metastasis in "Eye-Bulging" Breast Cancer PatientJul 10
Briacell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-Ots™? Metastatic Breast Cancer StudyJul 09
Briacell Therapeutics Corp. Reports Updated Survival Data from Its Ongoing Phase 2 Clinical Study of Bria-Imt in Patients with Metastatic Breast CancerJul 08
Briacell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital At Yale New HavenJul 02
BriaCell Announces Positive Recommendation from Data Safety Monitoring Board for Pivotal Phase 3 Study in Metastatic Breast CancerJun 24
BriaCell Therapeutics Corp. Reports Robust Overall Survival and Clinical Benefit Data at ASCO2025Jun 03
BriaCell Bria-OTS™ Phase 1/2 Study Clears Safety Evaluation; Doses First Patient in Combination with Checkpoint InhibitorMay 27
BriaCell Therapeutics Corp. Abstracts Showcase Positive Survival and Clinical Benefit Data At ASCO 2025May 23
BriaCell Therapeutics Corp. Reports " Late-Breaker" Phase 3 Data at AACR 2025: Positive Tolerability Profile and Potential Response Biomarkers IdentifiedApr 30
BriaCell Therapeutics Corp. Presents Benchmark Beating Survival and Clinical Benefit at AACR 2025Apr 28
BriaCell Therapeutics Corp. has completed a Composite Units Offering in the amount of CAD 13.8 million.Apr 26
Briacell Therapeutics Corp. Enrollment Pace Accelerating in Phase 3 Clinical Study in Advanced Metastatic Breast Cancer (Bria-ABC)Apr 22
Briacell Therapeutics Corp. Announces New Positive Survival Data in Its Phase 2 Study of Bria-Imt Plus Check Point InhibitorsApr 16
BriaCell Therapeutics Corp. Announces Second Data Safety Monitoring Board Issues Positive Recommendation to Continue BriaCell's Phase 3 Study in Metastatic Breast CancerMar 20
BriaCell Therapeutics Corp. has completed a Follow-on Equity Offering in the amount of CAD 3.05 million.Feb 06
BriaCell Therapeutics Corp. has completed a Composite Units Offering in the amount of $5.55 million.Dec 13
BriaCell Therapeutics Corp. Presents Unprecedented Overall Survival Data in Metastatic Breast Cancer in Spotlight Poster at 2024 SBCS®Dec 12
BriaCell Receives Green-Light from Data Safety Monitoring Board for Its Phase 3 Study in Metastatic Breast CancerDec 02
BriaCell Therapeutics Corp. Showcases Robust Anti-Cancer Activity of Personalized Off-the-Shelf Immunotherapy Pipeline at the 2024 SITC ConferenceNov 08
Briacell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival DataOct 22
BriaCell Therapeutics Corp. Provides Phase 3 Clinical Engagement Update in Metastatic Breast Cancer Pivotal StudyOct 15
BriaCell Therapeutics Corp. Reports 100% Resolution of Brain Metastasis in Breast Cancer Patient with "Eye-Bulging" TumorOct 02
BriaCell Therapeutics Corp. has completed a Follow-on Equity Offering in the amount of $8.50425 million.Sep 13
BriaCell Therapeutics Corp. has filed a Follow-on Equity Offering in the amount of $8.50425 million.Sep 12
BriaCell Therapeutics Corp. Announces Positive Overall Survival Data of its Phase 2 Clinical Study of Bria-IMT in Combination with an Immune Check Point InhibitorSep 11
BriaCell Therapeutics Receives Deficiency Letter from Nasdaq Due to Non-Compliance with the Minimum Bid Price RequirementAug 26
BriaCell Therapeutics Corp. Quadruples Progression Free Survival (Pfs) in Patient with "Eye-Bulging" Metastatic Breast CancerJul 19
BriaCell Therapeutics Receives Letter from Nasdaq Due to Non-Compliance with the Minimum Market Value of Listed Securities Requirement Pursuant to Nasdaq Listing Rule 5550(b)(2)Jul 06
BriaCell Therapeutics Corp. Initiates Patient Enrollment in First-In-Human Study of Bria-Ots in Advanced Metastatic Breast CancerMay 31
BriaCell Therapeutics Corp. has completed a Follow-on Equity Offering in the amount of $4.80586 million.May 18
BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+™ and Bria-PROS+™ Clinical Candidates for Breast and Prostate CancerApr 10
BriaCell Therapeutics Corp. Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder CaseFeb 08
Briacell Therapeutics Corp. Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates Gmp ManufacturingFeb 07
BriaCell Therapeutics Corp. Reports 71% Central Nervous System Response Rate in Advanced Breast Cancer PatientsDec 29
BriaCell Therapeutics Corp. Reports Unprecedented Preliminary Survival and Clinical Benefit in Antibody-Drug Conjugate Refractory Patient SubsetDec 20
BriaCell Therapeutics Corp. Highlights Outstanding Topline Survival and Clinical Benefit Data in Advanced Metastatic Breast Cancer at the 2023 SABCSDec 06
BriaCell Therapeutics Corp. Announces Anew Remarkable Responder in Phase 2 Study of the Bria-IMT Combination RegimenDec 01
BriaCell Reports Unprecedented Anti-Tumor Activity of its Next Generation Personalized Breast and Prostate Cancer Immunotherapies in Tumor Models at the 2023 SITC Annual Meeting; FDA Greenlights Bria-OTS™ INDNov 04
BriaCell Therapeutics Corp. Forms Medical Advisory Board of Distinguished Breast Cancer Specialists to Advance its Lead Oncology CandidateOct 26
BriaCell Therapeutics Corp. Initiates Pivotal Phase 3 Study of Bria-Imt™ in Advanced Metastatic Breast CancerOct 05
BriaCell Therapeutics Corp. Reports Benchmark-Beating Patient Survival and Clinical Benefit in Advanced Metastatic Breast CancerSep 09
BriaCell Therapeutics Corp. completed the Spin-Off of 33.33% stake in Pre-Clinical Assets of BriaCell Therapeutics Corp.Sep 01+ 1 more update
Briacell Receives National Cancer Institute Grant to Advance Its Bria-Ots™ Immunotherapy for CancerAug 17
FDA Approves BriaCell’s Pivotal Registrational Study Design in Advanced Metastatic Breast CancerJun 28
BriaCell Therapeutics Corp. Announces Positive End of Phase II Meeting with the FDA for Bria-IMT™ Combination in Advanced Metastatic Breast CancerJan 19